Arda Therapeutics Funding: $43M Raised, Series A (2024)
Arda Therapeutics is a Biotech company based in San Mateo, California. It has raised $43M in total funding. Latest round: Series A.
Arda Therapeutics funding overview
Arda Therapeutics is a Biotech company based in San Mateo, California. Arda Therapeutics has raised $43M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in September 2024. The round record for Arda Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Andreessen Horowitz, GV, Village Global, The Longevity Fund, a16z Bio + Health. 5 distinct backers are named across the disclosed rounds.
Arda Therapeutics at a glance
Total raised
$43M
Latest round
Series A
Latest round date
September 2024
Industry
Biotech
Headquarters
San Mateo, California
Notable investors
Andreessen Horowitz, GV, Village Global, The Longevity Fund, a16z Bio + Health
Frequently asked about Arda Therapeutics funding
How much has Arda Therapeutics raised?
Arda Therapeutics has raised $43M in total disclosed funding across the rounds on record.
Who has invested in Arda Therapeutics?
Andreessen Horowitz, GV, Village Global, The Longevity Fund, a16z Bio + Health are named among the investors backing Arda Therapeutics.
What was the latest Arda Therapeutics funding round?
The most recent disclosed round is a Series A, announced in September 2024.
Where is Arda Therapeutics based?
Arda Therapeutics is based in San Mateo, California.
What sector does Arda Therapeutics operate in?
Arda Therapeutics is tracked under Biotech from San Mateo, California, with $43M in disclosed funding.
When did Arda Therapeutics last raise?
The last disclosed Arda Therapeutics round closed in September 2024 at Series A.
Every Arda Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in San Mateo at a similar stage.
